Compare SNN & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNN | RDY |
|---|---|---|
| Founded | 1856 | 1984 |
| Country | United Kingdom | India |
| Employees | 16988 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 11.6B |
| IPO Year | N/A | 2001 |
| Metric | SNN | RDY |
|---|---|---|
| Price | $29.73 | $13.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $36.25 | $16.90 |
| AVG Volume (30 Days) | 1.3M | ★ 3.0M |
| Earning Date | 03-16-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.48% | 0.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.58 | $7.72 |
| Revenue Next Year | $5.60 | $3.50 |
| P/E Ratio | $64.97 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.23 | $12.19 |
| 52 Week High | $38.79 | $16.17 |
| Indicator | SNN | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 54.07 |
| Support Level | N/A | $12.90 |
| Resistance Level | $33.89 | $14.06 |
| Average True Range (ATR) | 0.57 | 0.27 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 19.76 | 72.70 |
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.